Anne Ducassou

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

Sylvie Bonvalot, Piotr Rutkowski, Juliette Thariat et al. · The Lancet Oncology · 2019 · 469 citations · Full text

Radiation Medicine, Radiation Therapy, Medicine +10

Effect on Survival of Local Ablative Treatment of Metastases from Sarcomas: A Study of the French Sarcoma Group

Alexander T. Falk, Laurence Moureau-Zabotto, M. Ouali et al. · Clinical Oncology · 2014 · 96 citations

Surgical Oncology, Malignant Disease, Local Ablative Treatment +8

αvβ3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase I–II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma

Anne Ducassou, Emmanuelle Uro‐Coste, Pierre Verrelle et al. · European Journal of Cancer · 2013 · 54 citations

Prognostic Factors, Neuro-oncology, Health Sciences +12

A CT-based radiomics classification model for the prediction of histological type and tumour grade in retroperitoneal sarcoma (RADSARC-R): a retrospective multicohort analysis

Amani Arthur, Matthew Orton, Robby Emsley et al. · The Lancet Oncology · 2023 · 50 citations · Full text

Retrospective Multicohort Analysis, Diagnostic Imaging, Medical Imaging +10

Improved nationwide survival of sarcoma patients with a network of reference centers

Jean‐Yves Blay, Nicolas Penel, Thibaud Valentin et al. · Annals of Oncology · 2024 · 44 citations · Full text